Table 2.
Characteristics of patients treated with DLI and/or 2nd HCT
| Variable | Total N (%) |
Survival ≥ 1 year post relapse N (%) |
|---|---|---|
| DLI±2nd HCT | 267 | 87 |
| DLI+chemotherapy | ||
| Yes | 216 (81) | 75 (86) |
| No | 51 (19) | 12 (14) |
| DLI‡+2nd HCT | ||
| +2nd HCT | 65 (24) | 30 (34) |
| No 2nd HCT | 202 (76) | 57 (66) |
| Type of donor | ||
| HLA-identical sibling | 162 (61) | 59 (68) |
| Unrelated | 102 (38) | 26 (30) |
| Missing | 3 (1) | 2 (2) |
| Donor Gender | ||
| Male | 144 (54) | 46 (53) |
| Female | 105 (39) | 38 (44) |
| Missing | 18 (7) | 3 (3) |
| Time from relapse to DLI | ||
| Median (range) | 2 (<1–12) | 2 (<1–12) |
| ≤6m | 226 (85) | 70 (80) |
| >6m | 11 (4) | 5 (6) |
| Missing | 25 (9) | 9 (10) |
| 2nd HCT | 369 | 182 |
| Conditioning | ||
| MA | 181 (49) | 99 (54) |
| RIC/NMA | 110 (30) | 57 (31) |
| Missing | 78 (21) | 26 (14) |
| Donor type of 2nd HCT | ||
| Related | 197 (53) | 94 (52) |
| Unrelated | 127 (34) | 70 (38) |
| Cord Blood | 20 (5) | 9 (5) |
| Missing | 25 (7) | 9 (5) |
| Donor gender | ||
| Male | 168 (46) | 78 (43) |
| Female | 126 (34) | 67 (37) |
| Missing | 75 (20) | 37 (20) |
| Same donor as 1st HCT | ||
| No | 81 (22) | 49 (27) |
| Yes | 166 (45) | 73 (40) |
| Missing | 122 (33) | 60 (33) |
| Time from relapse to 2nd HCT | ||
| Median (range) | 3 (<1–50) | 3 (<1–50) |
| ≤6m | 299 (81) | 135 (74) |
| >6m | 52 (14) | 40 (22) |
| Missing | 18 (5) | 7 (4) |
‡
Reflects DLI with or without chemotherapy